The FIPB, headed by Department of Economic Affairs Secretary Arvind Mayaram, in its September 19 meeting would also consider 30 other proposals, including six from the pharmaceutical sector.
Axis Bank had approached the FIPB last month soon after the RBI said the limit of investments through Global Depository Receipts (GDRs), American Depository Receipts (ADRs), FDI, NRI, FIIs in the bank had breached the overall limit of 49% of its paid-up capital.
Also Read
The country's fourth largest software services exporter had in July said it will raise investment limit for foreign institutional investors (FIIs) in the firm to 49% from 30%, subject to government approval.
The pharma sector proposals that would be discussed by the board include that of Shantha Biotechnics, Acebright (India) Pharma, SD Bio Standard Dignostics and Hyderabad-based Laurus Labs.
The other applications which are before the FIPB for consideration are that of manufacturer of military and civil helicopters Indian Rotocraft, Octania Aerostructure Group and Jubilant Aeronatics, among others.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)